ETHAMIDE
LOE ApproachingNDAORALTABLET
Approved
Oct 1966
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 5h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ETHAMIDE is an oral small-molecule tablet approved in 1966 under NDA by AbbVie. The specific mechanism of action and indication are not publicly documented in this dataset. This product represents a legacy oral therapeutic from the mid-20th century.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting defensive brand positioning and potential team downsizing or redeployment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ETHAMIDE currently has zero linked job openings, reflecting its mature LOE-approaching lifecycle. Career opportunities on this product are minimal; professionals should anticipate roles focused on managed decline, generic preparation, or reassignment to growth brands within AbbVie's portfolio.
Brand ManagerField Sales Representative
Worked on ETHAMIDE at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.